CN105056073A - 医治心律失常的中药制剂及制备方法 - Google Patents
医治心律失常的中药制剂及制备方法 Download PDFInfo
- Publication number
- CN105056073A CN105056073A CN201510537963.XA CN201510537963A CN105056073A CN 105056073 A CN105056073 A CN 105056073A CN 201510537963 A CN201510537963 A CN 201510537963A CN 105056073 A CN105056073 A CN 105056073A
- Authority
- CN
- China
- Prior art keywords
- parts
- subsequent use
- radix
- rhizoma
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims description 12
- 206010003119 arrhythmia Diseases 0.000 title abstract description 10
- 230000006793 arrhythmia Effects 0.000 title abstract description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 25
- 235000008434 ginseng Nutrition 0.000 claims abstract description 25
- 241001448530 Rohdea japonica Species 0.000 claims abstract description 23
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- 239000002994 raw material Substances 0.000 claims description 37
- 210000000582 semen Anatomy 0.000 claims description 36
- 239000000706 filtrate Substances 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 241000001482 Pedicularis davidii Species 0.000 claims description 27
- 241000208340 Araliaceae Species 0.000 claims description 25
- 244000063377 Phyllanthus simplex Species 0.000 claims description 21
- 241000612166 Lysimachia Species 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 20
- 230000001954 sterilising effect Effects 0.000 claims description 19
- 239000006187 pill Substances 0.000 claims description 17
- 241000251468 Actinopterygii Species 0.000 claims description 16
- 238000004659 sterilization and disinfection Methods 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 14
- 239000012467 final product Substances 0.000 claims description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 239000004570 mortar (masonry) Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 206010013786 Dry skin Diseases 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000000571 coke Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 26
- 210000002216 heart Anatomy 0.000 abstract description 23
- 208000024891 symptom Diseases 0.000 abstract description 14
- 230000002269 spontaneous effect Effects 0.000 abstract description 4
- 230000035900 sweating Effects 0.000 abstract description 4
- 206010033557 Palpitations Diseases 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 210000005036 nerve Anatomy 0.000 abstract description 2
- 241000010428 Alpinia katsumadae Species 0.000 abstract 1
- 244000060020 Chamaerops excelsa Species 0.000 abstract 1
- 235000013164 Chamaerops excelsa Nutrition 0.000 abstract 1
- 206010013954 Dysphoria Diseases 0.000 abstract 1
- 241000124846 Evolvulus alsinoides Species 0.000 abstract 1
- 241001620231 Ficus pandurata Species 0.000 abstract 1
- 241000060380 Nothapodytes Species 0.000 abstract 1
- 240000005178 Oxalis martiana Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000504571 Pedicularis muscicola Species 0.000 abstract 1
- 240000009019 Phyllanthus virgatus Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 244000126014 Valeriana officinalis Species 0.000 abstract 1
- 235000013832 Valeriana officinalis Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 235000016788 valerian Nutrition 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000002585 base Substances 0.000 description 15
- 239000000796 flavoring agent Substances 0.000 description 14
- 235000019634 flavors Nutrition 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 208000002173 dizziness Diseases 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 229930194931 Rhodexin Natural products 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 230000002936 tranquilizing effect Effects 0.000 description 6
- 230000008736 traumatic injury Effects 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 208000037920 primary disease Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- 229960004555 rutoside Drugs 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- LKZDFKLGDGSGEO-UJECXLDQSA-N kaempferol 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O[C@H](CO)[C@@H](O)[C@@H]1O LKZDFKLGDGSGEO-UJECXLDQSA-N 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000015817 Infant Nutrition disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000167859 Pedicularis Species 0.000 description 3
- HFMLTKBZNAPPNY-UHFFFAOYSA-N Rhodexin A Natural products OC1C(O)C(O)C(C)OC1OC1CC(CCC2C3(CCC(C3(C)CC(O)C32)C=2COC(=O)C=2)O)C3(C)CC1 HFMLTKBZNAPPNY-UHFFFAOYSA-N 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 208000004124 rheumatic heart disease Diseases 0.000 description 3
- NSPSSDCJLOQASC-FXRXPBCOSA-N rhodexin A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(CC[C@@H]([C@@]3(C)C[C@@H](O)[C@H]32)C=2CCC(=O)C=2)O)[C@]3(C)CC1 NSPSSDCJLOQASC-FXRXPBCOSA-N 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N (-)-7,7-Dimethyl-2-methylenebicyclo[2.2.1]heptane Chemical compound C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- LKZDFKLGDGSGEO-UHFFFAOYSA-N 2',8-Di-Me ether,7-O-beta-D-glucuronoside-2',5,7,8-Tetrahydroxyflavone Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)OC(CO)C(O)C1O LKZDFKLGDGSGEO-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010019705 Hepatic pain Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- ISQRJFLLIDGZEP-CMWLGVBASA-N Sophoricoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)C=C1 ISQRJFLLIDGZEP-CMWLGVBASA-N 0.000 description 2
- ISQRJFLLIDGZEP-KJRRRBQDSA-N Sophoricoside Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1 ISQRJFLLIDGZEP-KJRRRBQDSA-N 0.000 description 2
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 2
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- QQQCWVDPMPFUGF-ZDUSSCGKSA-N alpinetin Chemical compound C1([C@H]2OC=3C=C(O)C=C(C=3C(=O)C2)OC)=CC=CC=C1 QQQCWVDPMPFUGF-ZDUSSCGKSA-N 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003509 anti-fertility effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- PHHROXLDZHUIGO-UHFFFAOYSA-N dihydrovaltrate Chemical compound CC(C)CC(=O)OCC1=COC(OC(=O)CC(C)C)C2C1CC(OC(C)=O)C21CO1 PHHROXLDZHUIGO-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- RMZHSBMIZBMVMN-UHFFFAOYSA-N gamma-Selinene Chemical compound C1CCC(=C)C2CC(=C(C)C)CCC21C RMZHSBMIZBMVMN-UHFFFAOYSA-N 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- VHQQPFLOGSTQPC-UHFFFAOYSA-N pentatriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC VHQQPFLOGSTQPC-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 150000008265 rhamnosides Chemical class 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 210000001013 sinoatrial node Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- -1 valerianine Natural products 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- TVGPYTOYKLZBPA-UHFFFAOYSA-N (-)-Myrtenyl isovalerate Chemical compound CC(C)CC(=O)OCC1=CCC2C(C)(C)C1C2 TVGPYTOYKLZBPA-UHFFFAOYSA-N 0.000 description 1
- ITYNGVSTWVVPIC-DHGKCCLASA-N (-)-allo-Aromadendrene Chemical compound C([C@@H]1[C@H]2C1(C)C)CC(=C)[C@@H]1[C@H]2[C@H](C)CC1 ITYNGVSTWVVPIC-DHGKCCLASA-N 0.000 description 1
- CRPUJAZIXJMDBK-BDAKNGLRSA-N (-)-camphene Chemical compound C1C[C@H]2C(=C)C(C)(C)[C@@H]1C2 CRPUJAZIXJMDBK-BDAKNGLRSA-N 0.000 description 1
- 229930006714 (-)-camphene Natural products 0.000 description 1
- XMGQYMWWDOXHJM-SNVBAGLBSA-N (-)-α-limonene Chemical compound CC(=C)[C@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-SNVBAGLBSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-VIFPVBQESA-N (R)-(+)-alpha-terpineol Chemical compound CC1=CC[C@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-VIFPVBQESA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WNRBYZQFEBIUGD-UHFFFAOYSA-N 3,7(11)-Eudesmadiene Natural products C1CC=C(C)C2CC(=C(C)C)CCC21C WNRBYZQFEBIUGD-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- ZHQQRIUYLMXDPP-SSDOTTSWSA-N Actinidine Natural products C1=NC=C(C)C2=C1[C@H](C)CC2 ZHQQRIUYLMXDPP-SSDOTTSWSA-N 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- ITYNGVSTWVVPIC-XGFWRYKXSA-N Alloaromadendrene Natural products C([C@@H]1[C@H]2C1(C)C)CC(=C)[C@@H]1[C@@H]2[C@H](C)CC1 ITYNGVSTWVVPIC-XGFWRYKXSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- NYSZJNUIVUBQMM-BQYQJAHWSA-N Cardamonin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 NYSZJNUIVUBQMM-BQYQJAHWSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 1
- ORJDDOBAOGKRJV-UHFFFAOYSA-N Dihydrotectochrysin Natural products O1C2=CC(OC)=CC(O)=C2C(=O)CC1C1=CC=CC=C1 ORJDDOBAOGKRJV-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- CKZXONNJVHXSQM-UHFFFAOYSA-N Ledol Natural products CC(C)C1CCC(C)(O)C2C3CC(C)CC123 CKZXONNJVHXSQM-UHFFFAOYSA-N 0.000 description 1
- AYXPYQRXGNDJFU-AOWZIMASSA-N Ledol Chemical compound [C@@H]1([C@](CC[C@@H]2[C@H]3C2(C)C)(C)O)[C@H]3[C@H](C)CC1 AYXPYQRXGNDJFU-AOWZIMASSA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- CJRKEDMYNFITCQ-UHFFFAOYSA-N Maaliol Natural products C1CCC(C)(O)C2C3C(C)(C)C3CCC21C CJRKEDMYNFITCQ-UHFFFAOYSA-N 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 241000522308 Oxalis pes-caprae Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 241000208476 Primulaceae Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241001417494 Sciaenidae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- HIWPGCMGAMJNRG-ACCAVRKYSA-N Sophorose Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HIWPGCMGAMJNRG-ACCAVRKYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- RJZWGDPBGWGJNU-MTXIQXFFSA-N Valerenal Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C=O)C2=C(C)CC[C@H]12 RJZWGDPBGWGJNU-MTXIQXFFSA-N 0.000 description 1
- RJZWGDPBGWGJNU-OQDDGJPTSA-N Valerenal Natural products O=C/C(=C\[C@H]1C2=C(C)CC[C@@H]2[C@H](C)CC1)/C RJZWGDPBGWGJNU-OQDDGJPTSA-N 0.000 description 1
- XJNQXTISSHEQKD-HIPMNCMDSA-N Valerenolic Acid Chemical compound C[C@@H]1CC[C@@H](C=C(C)C(O)=O)C2=C(C)C[C@@H](O)[C@H]12 XJNQXTISSHEQKD-HIPMNCMDSA-N 0.000 description 1
- XJNQXTISSHEQKD-UHFFFAOYSA-N Valerenolic acid Natural products CC1CCC(C=C(C)C(O)=O)C2=C(C)CC(O)C12 XJNQXTISSHEQKD-UHFFFAOYSA-N 0.000 description 1
- 241000792902 Valerianaceae Species 0.000 description 1
- ZRJLCVQCZVXUFB-QMMMGPOBSA-N Valerianine Chemical compound COCC1=CN=CC2=C1CC[C@@H]2C ZRJLCVQCZVXUFB-QMMMGPOBSA-N 0.000 description 1
- ZRJLCVQCZVXUFB-MRVPVSSYSA-N Valerianine Natural products O(Cc1c2c([C@H](C)CC2)cnc1)C ZRJLCVQCZVXUFB-MRVPVSSYSA-N 0.000 description 1
- LANCLZFYVLANQS-RHMPUOGUSA-N Valerosidatum Chemical compound O([C@H]([C@@H]1[C@](C)(O)[C@@H](O)C[C@@H]11)OC(=O)CC(C)C)C=C1CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LANCLZFYVLANQS-RHMPUOGUSA-N 0.000 description 1
- BDIAUFOIMFAIPU-KVJIRVJXSA-N Valtratum Chemical compound C([C@]12[C@@H]3C(C(=CO[C@H]3OC(=O)CC(C)C)COC(C)=O)=C[C@@H]1OC(=O)CC(C)C)O2 BDIAUFOIMFAIPU-KVJIRVJXSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 1
- GOENJWUGVSLZDQ-JBWWEBJPSA-N [7-[(z)-2-methylbut-2-enoyl]oxy-5,6,7,8-tetrahydro-3h-pyrrolizin-1-yl]methyl (e)-2-(hydroxymethyl)but-2-enoate Chemical compound C1C=C(COC(=O)C(\CO)=C\C)C2C(OC(=O)C(\C)=C/C)CCN21 GOENJWUGVSLZDQ-JBWWEBJPSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- ZHQQRIUYLMXDPP-ZETCQYMHSA-N actinidine Chemical compound C1=NC=C(C)C2=C1[C@@H](C)CC2 ZHQQRIUYLMXDPP-ZETCQYMHSA-N 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- SZCHXNLVRKQEGO-XKDXWZMYSA-N alkaloid b Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1C[C@H](O)C2=CC1=C3OCO1 SZCHXNLVRKQEGO-XKDXWZMYSA-N 0.000 description 1
- 229930016183 alpha-curcumene Natural products 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- JVEMWXSMSUNXSD-UHFFFAOYSA-N alpinetin Natural products C=1C(=O)C=2C(OC)=CC(O)=CC=2OC=1C1=CC=CC=C1 JVEMWXSMSUNXSD-UHFFFAOYSA-N 0.000 description 1
- NYSZJNUIVUBQMM-UHFFFAOYSA-N alpinetin chalcone Natural products COC1=CC(O)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 NYSZJNUIVUBQMM-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- HIWPGCMGAMJNRG-UHFFFAOYSA-N beta-sophorose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)C(CO)O1 HIWPGCMGAMJNRG-UHFFFAOYSA-N 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 210000001326 carotid sinus Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- PMBXAKHNZRLXJE-UHFFFAOYSA-N comosine Natural products COC1CC23C(CCN2CCCc2cc4OCOc4cc32)C=C1 PMBXAKHNZRLXJE-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000009609 fructus phyllanthi Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- NLAGNNORBYGNAV-UHFFFAOYSA-N isotriacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCC(C)C NLAGNNORBYGNAV-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- CJRKEDMYNFITCQ-MUGBGTHKSA-N maalialcohol Chemical compound C1CC[C@](C)(O)[C@H]2[C@@H]3C(C)(C)[C@@H]3CC[C@@]21C CJRKEDMYNFITCQ-MUGBGTHKSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- PZDOWFGHCNHPQD-VNNZMYODSA-N sophorose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-VNNZMYODSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 229940068146 valepotriate Drugs 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- FEBNTWHYQKGEIQ-SUKRRCERSA-N valerenic acid Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C(O)=O)C2=C(C)CC[C@H]12 FEBNTWHYQKGEIQ-SUKRRCERSA-N 0.000 description 1
- FUHPCDQQVWLRRY-UHFFFAOYSA-N valerenic acid Natural products CC1CCC(C=C(/C)C(=O)O)C2C1CC=C2C FUHPCDQQVWLRRY-UHFFFAOYSA-N 0.000 description 1
- JRRUATLDNQIXRC-UHFFFAOYSA-N valerosidatum Natural products CC(C)CC(=O)OC1OCC(COC2OC(CO)C(O)C(O)C2O)C3CC(O)C(C)(O)C13 JRRUATLDNQIXRC-UHFFFAOYSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000008852 wen-xin Substances 0.000 description 1
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 1
- USDOQCCMRDNVAH-KKUMJFAQSA-N β-cadinene Chemical compound C1C=C(C)C[C@H]2[C@H](C(C)C)CC=C(C)[C@@H]21 USDOQCCMRDNVAH-KKUMJFAQSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种医治心律失常的中药制剂,由下列原料药制备而成,均为重量份:白芍10-15;太白参8-16;石首鱼9-14;缬草4-9;万年青7-14;槐角6-12;黄珠子草8-13;土丁桂7-12;棕树心9-13;人参11-16;草豆蔻7-15;琴叶榕9-12;铜锤草10-13;琥珀8-12;追风伞9-15。本发明的优良效果还表现在:本发明药物可以达到清热除烦,宁心安神,解肌敛汗的目的,对于心律失常表现的心悸、烦躁、自汗等症状具有明显缓解作用;本发明所得药物安全可靠,疗效肯定,药源易得,药材成本低廉,能够减轻患者负担。
Description
技术领域
本发明涉及中医中药领域,特别是涉及一种医治心律失常的中药制剂及制备方法。
背景技术
心律失常是由于窦房结激动异常或激动产生于窦房结以外,激动的传导缓慢、阻滞或经异常通道传导,即心脏活动的起源和(或)传导障碍导致心脏搏动的频率和(或)节律异常。心律失常是心血管疾病中重要的一组疾病。它可单独发病亦可与心血管病伴发。可突然发作而致猝死,亦可持续累及心脏而致其衰竭。
心律失常可见于各种器质性心脏病,其中以冠状动脉粥样硬化性心脏病(简称冠心病),心肌病,心肌炎和风湿性心脏病(简称风心病)为多见,尤其在发生心力衰竭或急性心肌梗塞时,发生在基本健康者或植物神经功能失调患者中的心律失常也不少见,其他病因尚有电解质或内分泌失调,麻醉,低温,胸腔或心脏手术,药物作用和中枢神经系统疾病等。本病的发病率因年龄的增加而增加,因此是中老年人常见的病症,特别是在我国老年化不断深入的时代,其发病率有明显增高的趋势。
心律失常属于中医“心悸”范畴。本病的临床表现轻重不一,中医认为本病为本虚标实,虚实夹杂之证。本虚主要是心脏或兼有其它脏腑的气血、阴阳的亏虚,病邪主要分为寒、热、痰、气滞和淤血。现代多数医家认为本病的发生,常由于脏腑功能失调,气血亏虚,肝郁气滞,痰湿内滞,心脉瘀阻所致。故益气补肾、活血化瘀、行气活血、清热泻火、宁心安神等为其主要的治疗方法。
申请公布号CN102973887A(申请号201210459686.1)的中国发明专利文献公开了一种治疗心律失常的中药,由以下重量配比的原料制成:藏红花13-17、牛膝6-10、白芍4-8、当归13-17、黄芪13-17、麦冬10-14、三果木皮6-10、白术4-8、刺五茄10-14、麦冬6-10、郁金4-8、木香1-5、陈皮13-17、泽兰6-10、枳壳6-10、西洋参10-14。申请公布号CN104666977A(申请号201310635520.5)的中国发明专利文献公开了一种治疗心律失常的中药,由以下重量配比的原料制成:炒枣仁28-32克,菟丝子10-14克,枸杞子8-12克,白术10-14克,炒槐米10-14克,海藻8-12克,天冬10-14克,鸡内金10-14克,柏子仁10-14克,钩藤8-12克,天竺黄1-5克,三七粉1-5克。申请公布号CN104173916A(申请号201410361176.X)的中国发明专利文献公开了一种治疗心律失常的中药制剂,由以下重量份的原料制成:当归10份、赤芍10份、红花9份、琥珀8份、广郁金9份、川芎9份、失笑散8份、柴胡10份、枳壳12份。
目前,西药一般只能减轻病人的痛苦,去除病人的临床表现而不能根除此病达到治愈的目的。中医治疗本病特别强调整体观念、辨证论治的观点,具有一定优势,且中药价廉、毒副作用小、对器官影响不大,值得大力开发推广使用。
发明内容
针对现有技术的不足,本发明的目的是提供一种制备简单、方便服用、安全有效的医治心律失常的中药制剂。该中药制剂疗效显著,无任何副作用。
本发明的技术方案是:
医治心律失常的中药制剂,由下列原料药制备而成,均为重量份:白芍10-15;太白参8-16;石首鱼9-14;缬草4-9;万年青7-14;槐角6-12;黄珠子草8-13;土丁桂7-12;棕树心9-13;人参11-16;草豆蔻7-15;琴叶榕9-12;铜锤草10-13;琥珀8-12;追风伞9-15。
优选的方案中,白芍11-14;太白参10-14;石首鱼10-13;缬草5-8;万年青9-12;槐角8-10;黄珠子草9.5-11.5;土丁桂8.5-10.5;棕树心10-12;人参12.5-14.5;草豆蔻9-13;琴叶榕10-11;铜锤草11-12;琥珀9-11;追风伞11-13。
更加优选的,白芍12.5;太白参12;石首鱼11.5;缬草6.5;万年青10.5;槐角9;黄珠子草10.5;土丁桂9.5;棕树心11;人参13.5;草豆蔻11;琴叶榕10.5;铜锤草11.5;琥珀10;追风伞12。
医治心律失常的中药制剂,将其制成药学上可接受的丸剂,制备方法如下:
(1)取石首鱼肉置于容器中,加入15%原料药量的黄酒拌匀,焖6-14分钟(优选焖10分钟),然后捣碎成泥状,备用;琥珀研成细粉,置乳钵中,水飞至无声为度,干燥,备用;
(2)取太白参、人参和棕树心置于砂锅内,加3-5倍量的清水(优选加4倍量的清水),文火加热煎煮25-45分钟(优选文火加热煎煮35分钟),过滤,滤液备用;
(3)取缬草、万年青、黄珠子草、草豆蔻、琴叶榕和铜锤草于68-76℃干燥26-42分钟(优选于72℃干燥34分钟),然后置于粉碎机中粉碎成细粉,备用;
(4)将白芍、槐角、土丁桂和追风伞置于药锅内,加冷水没过药面3-4cm,大火加热至沸,转小火煎煮22-46分钟(优选转小火煎煮34分钟),过滤,滤液与步骤(2)所得滤液合并,减压浓缩至原体积的的1/4,备用;
(5)将步骤(1)和(3)处理后的原料要加入到步骤(4)所得滤液中,加入其它辅料,搅拌均匀,干热灭菌,加工成赤豆大小的丸剂,即得。
上述医治心律失常的中药丸剂的制备方法,优选的方案是,步骤(5)中所述辅料为质量分数为10%的乳糖细粉和质量分数为6%的玉米淀粉。
上述医治心律失常的中药丸剂的制备方法,优选的方案是,步骤(5)中干热灭菌的温度为85-105℃(优选的干热灭菌的温度为90-100℃,更加优选的干热灭菌的温度为95℃)。
上述医治心律失常的中药丸剂的制备方法,优选的方案是,步骤(5)中干热灭菌的时间为32-54分钟(优选的干热灭菌的时间为38-48分钟,更加优选的干热灭菌的时间为43分钟)。
所述胶囊剂的制备方法是:
(1)取石首鱼肉、太白参、人参和土丁桂置于药锅内,加冷水没过药面3-5cm,然后中火煎煮18-36分钟(优选中火煎煮27分钟),过滤,滤液减压浓缩至原体积的1/3,备用;
(2)取草豆蔻加姜汁拌匀(草豆蔻:生姜=20:1),待姜汁被吸尽后,置炒制容器内,文火加热炒干,取出晾凉,捣碎成细粉,备用;琥珀研成细粉,置乳钵中,水飞至无声为度,干燥,备用;
(3)将除步骤(1)和(2)以外的原料药置于中药提取器中,以乙醇和水为溶剂(乙醇和水的体积比为1:2.5),溶剂的量为原料药量的4-7倍(优选溶剂的量为原料药量的5.5倍),加热回流提取两次,第一次提取22-48分钟(优选第一次提取35分钟),第二次提取10-24分钟(优选第二次提取17分钟),合并两次提取液,过滤,回收乙醇,减压蒸馏至80℃相对密度为1.30-1.33的稠膏,备用;
(4)将步骤(1)和(2)处理后的原料药加入到上述稠膏中,机械搅拌,同时加入其它辅料(辅料为质量分数为9.5%的糊精细粉和质量分数为5.5%的微晶纤维素),混合均匀,制粒,整粒,干燥,过六号筛,装入胶囊壳,即得。
所述片剂的制备方法是:
(1)取石首鱼肉加入15%原料药量的黄酒拌匀,置于蒸锅内,大火加热蒸熟为度,取出,捣碎成泥状,备用;
(2)草豆蔻、槐角、棕树心、琥珀、人参和太白参置于烘箱内,于45-65℃干燥1-3小时(优选于55℃干燥2小时),捣碎,并研细粉,备用;
(3)将除步骤(1)和(2)以外的原料药加3.5-6.5倍量的清水文火煎煮两次(优选加5倍量的清水文火煎煮两次),第一次煎煮32-50分钟(优选第一次煎煮40分钟),第二次煎煮11-33分钟(优选第二次煎煮22分钟),合并两次减压,过滤,滤液减压浓缩至75℃相对密度为1.25-1.28的稠膏,冷却至室温,加浓度为80%的乙醇,使含醇量为45%,静置20-30小时(优选静置25小时),过滤,滤液回收乙醇,减压浓缩至80℃相对密度为1.31-1.33的稠膏,备用;
(4)将步骤(1)处理后的石首鱼肉以及步骤(2)所得原料药粉加入到上述稠膏中,喷雾干燥得干膏粉,边搅拌边加入乳糖细粉和硬脂酸镁,干膏粉与乳糖细粉和硬脂酸镁的质量比为6:1.1:0.8,混合均匀,置于压片机中压成片剂,即得。
所述水剂的制备方法是:
(1)取槐角洗净,武火炒至表面焦黑色,内部深黄色,取出放凉,研细粉,备用;草豆蔻文火加热,炒至微黄色并有香气逸出为度,取出晾凉,捣碎成细粉,备用;琥珀置于研钵中研细粉,备用;
(2)取石首鱼肉、太白参和人参加清水没过药面3-4cm,文火加热煎煮26-46分钟(优选文火加热煎煮36分钟),过滤,滤液备用;
(3)棕树心、土丁桂、琴叶榕和追风伞混合,加入25%-35%原料药量的黄酒拌匀(优选加入30%原料药量的黄酒拌匀),焖1-3小时(优选焖2小时),取出,备用;
(4)将步骤(3)处理后的原料药与白芍、缬草、万年青、黄珠子草和铜锤草一同置于砂锅内,加5-7倍原料药量的清水(优选加6倍原料药量的清水),文火煎煮35-55分钟(优选文火煎煮45分钟),过滤,滤液备用;
(5)将步骤(2)和(4)所得滤液合并,减压浓缩至原体积的1/3,然后加入步骤(1)处理后的原料药粉,搅拌均匀,灭菌封装,即得。
本发明组方科学,制备方法简单,服用方便、效果显著。除此之外,本发明的优良效果还表现在:
1、本发明将传统药性与中药现代药理有机结合,遣药组方,直入病所,增进疗效;
2、本发明药物可以达到清热除烦,宁心安神,解肌敛汗的目的,对于心律失常表现的心悸、烦躁、自汗等症状具有明显缓解作用;
3、本发明所得药物安全可靠,疗效肯定,药源易得,药材成本低廉,能够减轻患者负担。
具体实施方式
下面结合实施例和实验例详细说明本发明的技术方案,但保护范围不限于此。
实施例1医治心律失常的中药制剂,由下列原料药制备而成,均为重量份(45g/份):白芍10份;太白参8份;石首鱼9份;缬草4份;万年青7份;槐角6份;黄珠子草8份;土丁桂7份;棕树心9份;人参11份;草豆蔻7份;琴叶榕9份;铜锤草10份;琥珀8份;追风伞9份。
医治心律失常的中药丸剂的制备方法是:
(1)取石首鱼肉置于容器中,加入15%原料药量的黄酒拌匀,焖6分钟,然后捣碎成泥状,备用;琥珀研成细粉,置乳钵中,水飞至无声为度,干燥,备用;
(2)取太白参、人参和棕树心置于砂锅内,加3倍量的清水,文火加热煎煮25分钟,过滤,滤液备用;
(3)取缬草、万年青、黄珠子草、草豆蔻、琴叶榕和铜锤草于68℃干燥26分钟,然后置于粉碎机中粉碎成细粉,备用;
(4)将白芍、槐角、土丁桂和追风伞置于药锅内,加冷水没过药面3-4cm,大火加热至沸,转小火煎煮22分钟,过滤,滤液与步骤(2)所得滤液合并,减压浓缩至原体积的的1/4,备用;
(5)将步骤(1)和(3)处理后的原料要加入到步骤(4)所得滤液中,加入其它辅料(辅料为质量分数为10%的乳糖细粉和质量分数为6%的玉米淀粉),搅拌均匀,85℃干热灭菌32分钟,加工成赤豆大小的丸剂,即得。
本发明所得丸剂的服用方法是:每天三次,每次8-10丸,温水送服,7天一个疗程。
典型病例:张XX,女,47岁,郓城人,患者自述:两年前无明显诱突发胸闷、心悸,头晕乏力,每次发作约持续20分钟,卧床休息后症状可自行缓解,一直未多加重视。最近半个月突然出现胸闷、心悸,伴头晕、全身无力,休息后也未缓解,经人介绍于2010年7月17日来我院就诊。检查:T36.7℃,P151次/分,R22次/分,BP93/60mmHg,神志清醒,面色?白,呼吸平稳,心率135次/分,律齐,辅助检查:急诊胸片未见明显异常,急诊心电图示室上性心动过速。结合患者病史、症状、体征及辅助检查结果,诊断为心律失常-阵发性室上性心动过速。
服用本实施例所得医治心律失常的中药丸剂,服用方法:每天三次,每次8-10丸,温水送服,7天一个疗程。服用两个疗程后,患者胸闷、心悸症状明显减轻,精神可,继续用药两个疗程,心电图基本恢复正常,患者不适症状消失,自感痊愈。停药半年后回访,无复发。
实施例2医治心律失常的中药制剂,由下列原料药制备而成,均为重量份(25g/份):白芍15份;太白参16份;石首鱼14份;缬草9份;万年青14份;槐角12份;黄珠子草13份;土丁桂12份;棕树心13份;人参16份;草豆蔻15份;琴叶榕12份;铜锤草13份;琥珀12份;追风伞15份。
医治心律失常的中药胶囊剂的制备方法是:
(1)取石首鱼肉、太白参、人参和土丁桂置于药锅内,加冷水没过药面3-5cm,然后中火煎煮27分钟,过滤,滤液减压浓缩至原体积的1/3,备用;
(2)取草豆蔻加姜汁拌匀(草豆蔻:生姜=20:1),待姜汁被吸尽后,置炒制容器内,文火加热炒干,取出晾凉,捣碎成细粉,备用;琥珀研成细粉,置乳钵中,水飞至无声为度,干燥,备用;
(3)将除步骤(1)和(2)以外的原料药置于中药提取器中,以乙醇和水为溶剂(乙醇和水的体积比为1:2.5),溶剂的量为原料药量的5.5倍,加热回流提取两次,第一次提取35分钟,第二次提取17分钟,合并两次提取液,过滤,回收乙醇,减压蒸馏至80℃相对密度为1.31的稠膏,备用;
(4)将步骤(1)和(2)处理后的原料药加入到上述稠膏中,机械搅拌,同时加入其它辅料(辅料为质量分数为9.5%的糊精细粉和质量分数为5.5%的微晶纤维素),混合均匀,制粒,整粒,干燥,过六号筛,装入胶囊壳,即得。
本发明所得胶囊剂的服用方法是:每天三次,每次4-5粒,温水送服,7天一个疗程。
实施例3医治心律失常的中药制剂,由下列原料药制备而成,均为重量份(40g/份):白芍11份;太白参10份;石首鱼10份;缬草5份;万年青9份;槐角8份;黄珠子草9.5份;土丁桂8.5份;棕树心10份;人参12.5份;草豆蔻9份;琴叶榕10份;铜锤草11份;琥珀9份;追风伞11份。
医治心律失常的中药片剂的制备方法是:
(1)取石首鱼肉加入15%原料药量的黄酒拌匀,置于蒸锅内,大火加热蒸熟为度,取出,捣碎成泥状,备用;
(2)草豆蔻、槐角、棕树心、琥珀、人参和太白参置于烘箱内,于55℃干燥2小时,捣碎,并研细粉,备用;
(3)将除步骤(1)和(2)以外的原料药加5倍量的清水文火煎煮两次,第一次煎煮40分钟,第二次煎煮22分钟,合并两次减压,过滤,滤液减压浓缩至75℃相对密度为1.26的稠膏,冷却至室温,加浓度为80%的乙醇,使含醇量为45%,静置25小时,过滤,滤液回收乙醇,减压浓缩至80℃相对密度为1.32的稠膏,备用;
(4)将步骤(1)处理后的石首鱼肉以及步骤(2)所得原料药粉加入到上述稠膏中,喷雾干燥得干膏粉,边搅拌边加入乳糖细粉和硬脂酸镁,干膏粉与乳糖细粉和硬脂酸镁的质量比为6:1.1:0.8,混合均匀,置于压片机中压成片剂,即得。
本发明所得片剂的服用方法是:每天三次,每次4-6片,温水送服,7天一个疗程。
典型病例:范XX,男,43岁,济南人。患者自述:4个月前,酒后意外出现心慌症状,无明显胸痛等其它症状。自此后心慌经常发作,每次可持续20分钟,身体并无其它明显不适。故未能及时检查就诊。一周前患者心慌发作,伴胸闷气短、头晕症状。于2011年10月25日来我院检查就诊。检查:患者血压132/95mmHg,精神状态可,心率80BPM,律齐,无杂音。心电图检查:窦性心律及偶发室性早搏。
服用本实施例所得医治心律失常的中药片剂,服用方法:每天三次,每次4-6片,温水送服,7天一个疗程。用药两个疗程后,患者心慌、头晕、胸闷等症状明显减轻,发作次数减少,体力增,精神可,继续用药两个疗程,心电图检查正常,患者自感痊愈,半年后回访,无复发。
实施例4医治心律失常的中药制剂,由下列原料药制备而成,均为重量份(30g/份):白芍14份;太白参14份;石首鱼13份;缬草8份;万年青12份;槐角10份;黄珠子草11.5份;土丁桂10.5份;棕树心12份;人参14.5份;草豆蔻13份;琴叶榕11份;铜锤草12份;琥珀11份;追风伞13份。
医治心律失常的中药水剂的制备方法是:
(1)取槐角洗净,武火炒至表面焦黑色,内部深黄色,取出放凉,研细粉,备用;草豆蔻文火加热,炒至微黄色并有香气逸出为度,取出晾凉,捣碎成细粉,备用;琥珀置于研钵中研细粉,备用;
(2)取石首鱼肉、太白参和人参加清水没过药面3-4cm,文火加热煎煮36分钟,过滤,滤液备用;
(3)棕树心、土丁桂、琴叶榕和追风伞混合,加入30%原料药量的黄酒拌匀,焖2小时,取出,备用;
(4)将步骤(3)处理后的原料药与白芍、缬草、万年青、黄珠子草和铜锤草一同置于砂锅内,加6倍原料药量的清水,文火煎煮45分钟,过滤,滤液备用;
(5)将步骤(2)和(4)所得滤液合并,减压浓缩至原体积的1/3,然后加入步骤(1)处理后的原料药粉,搅拌均匀,灭菌封装,即得。
本发明所得水剂的服用方法是:每天三次,每次100-120mL,温热服用,7天一个疗程。
实施例5医治心律失常的中药制剂,由下列原料药制备而成,均为重量份(35g/份):白芍12.5份;太白参12份;石首鱼11.5份;缬草6.5份;万年青10.5份;槐角9份;黄珠子草10.5份;土丁桂9.5份;棕树心11份;人参13.5份;草豆蔻11份;琴叶榕10.5份;铜锤草11.5份;琥珀10份;追风伞12份。
医治心律失常的中药丸剂的制备方法是:
(1)取石首鱼肉置于容器中,加入15%原料药量的黄酒拌匀,焖10分钟,然后捣碎成泥状,备用;琥珀研成细粉,置乳钵中,水飞至无声为度,干燥,备用;
(2)取太白参、人参和棕树心置于砂锅内,加4倍量的清水,文火加热煎煮35分钟,过滤,滤液备用;
(3)取缬草、万年青、黄珠子草、草豆蔻、琴叶榕和铜锤草于72℃干燥34分钟,然后置于粉碎机中粉碎成细粉,备用;
(4)将白芍、槐角、土丁桂和追风伞置于药锅内,加冷水没过药面3-4cm,大火加热至沸,转小火煎煮34分钟,过滤,滤液与步骤(2)所得滤液合并,减压浓缩至原体积的的1/4,备用;
(5)将步骤(1)和(3)处理后的原料要加入到步骤(4)所得滤液中,加入其它辅料(辅料为质量分数为10%的乳糖细粉和质量分数为6%的玉米淀粉),搅拌均匀,95℃干热灭菌43分钟,加工成赤豆大小的丸剂,即得。
本发明所得丸剂的服用方法是:每天三次,每次8-10丸,温水送服,7天一个疗程。
本发明所用主要中药原料的药理如下:
白芍:基原:本品为毛茛科植物芍药的干燥根。化学成份:根含芍药甙、牡丹酚、芍药花甙,苯甲酸约1。07%、挥发油、脂肪油、树脂、鞣质、糖、淀粉、粘液质、蛋白质、β-谷甾醇和三萜类。性味:苦、酸,微寒。归经:归肝、脾经。功效:平肝止痛,养血调经,敛阴止汗。主治:用于头痛眩晕,胁痛,腹痛,四肢挛痛,血虚萎黄,月经不调,自汗,盗汗。
太白参:基原:为玄参科植物大卫马先蒿、美观马先蒿、邓氏马先蒿的根。性味:味甘;微苦;性温;小毒。功能主治:滋阴补肾;益气健脾。主脾肾两虚;骨蒸潮热;关节疼痛;不思饮食。
石首鱼:基原:为石首鱼科动物大黄鱼或小黄鱼的肉。化学成份:食用部分含蛋白质,脂肪,灰分,钙,磷,铁,硫胺素(thiamine),核黄素(riboflavin),烟酸(nicotinicacid),碘等。性味:味甘;性平。归经:脾;胃;肝;肾经。功能主治:益气健脾;补肾;明目;止痢。主病后、产后体虚;乳汁不足;肾虚腰痛;水肿;视物昏花;头痛;胃痛;泻痢。
缬草:基原:为败酱科植物缬草的根及根茎。化学成份:根含挥发油0.5~2%,主成分为异戊酸龙脑酯;还含龙脑、l-莰烯、α-蒎烯、d-松油醇、l-柠檬烯、吡咯基-α-甲基甲酮、α-葑烯、月桂烯。水芹烯、l-石竹烯、γ-松油烯、异松油烯、雅槛蓝树油烯、别香橙烯、毕澄茄烯、γ-芹子烯、缬草萜烯醇、橙皮酸、缬草烯酸、山萮酸、缬草萜醇酸、异戊酸、缬草酮、缬草烯醛、甘松香油醇、乙酸龙脑酯、l-桃金娘醇,乙酸桃金娘酯、异戊酸桃金娘酯、β-甜汉药烯、α-姜黄烯、喇叭醇等。又含缬草碱、鬃草宁碱、缬草生物碱A、缬草生物碱B、猕猴桃碱、缬草宁碱等生物碱。尚含缬草三酯、异戊酰氧基二氢缬草三酯、缬草环臭蚁醛酯甙、咖啡酸、绿原酸、鞣质、树脂、β-谷甾醇等。药理作用:①对神经系统的作用:缬草有镇静作用,能加强大脑皮层的抑制过程,减低反射兴奋性,解除平滑肌痉挛。②对循环、呼吸的作用:缬草中某些成分对动物(犬、猫、兔、小鼠)有降低血压的作用,此作用与其拟副交感样作用、阻断颈动脉窦反射及抑制中枢神经系统有关。③抗菌作用:从缬草中提出的总生物碱有抗菌作用,特别是对革兰氏阳性细菌效力较好。从其中分出的两种生物碱-缬草碱、鬃草宁碱亦有作用,但效力较低。④其他作用:有某些抗利尿作用。性味:①《四川中药志》:“味辛苦,性温,有微毒。”②《新疆中草药手册》:“味辛微甘,性温,无毒。”归经:《四川中药志》:“入心、肝二经。”功能主治:治心神不安,胃弱,腰痛,月经不调,跌打损伤。
万年青:基原:为百合科万年青属植物万年青,以根状茎或全草入药。化学成份:叶及根状茎含有强心甙类:万年青甙甲、乙、丙及皂甙。万年青甙甲为沙门甙元的鼠李糖甙,万年青甙乙为夹竹桃甙元的鼠李糖甙,万年青甙丙为夹竹桃甙元-鼠李糖-葡萄糖甙。据近报道,叶含有万年青甙丁及β-谷甾醇葡萄糖甙。鲜叶及根状茎含万年青甙甲约0.008%,万年青甙丙约0.03%。干叶含粗总甙约0.43%,万年青甙丁约0.1%。药理作用:1、万年青甙增强心肌的收缩力,并能兴奋迷走神经和抑制心肌的传导,使心率减慢,并有利尿作用。2、万年青稀溶液仅使肠血管收缩,对冠状血管、肾脏血管、脑血管及四肢血管等则使之扩张;较浓的溶液因直接作用于血管壁,可使各种组织、器官的血管均收缩。3、对胃肠及子宫平滑肌有兴奋作用,可增强其收缩。4、毒性实验:静脉注射最小致死量,猫每公斤体重为0.091毫克,家兔每公斤为0.29毫克,以1/3的最小致死量注射于猫的皮下,于6小时内发生剧烈呕吐,并有较大的蓄积作用。5、抑菌试验:酊剂用试管稀释法,1:512对白喉杆菌,1:128对金黄色葡萄球菌、乙型链球菌及枯草杆菌等均有抑制作用。6、本品醋剂作用弱于酊剂,煎剂无效。性味:苦、甘、寒。有小毒。归经:肺;心经。功能主治:清热解毒,强心利尿。用于防治白喉,白喉引起的心肌炎,咽喉肿痛,狂犬咬伤,细菌性痢疾,风湿性心脏病心力衰竭;外用治跌打损伤,毒蛇咬伤,烧烫伤,乳腺炎,痈疖肿毒。
槐角:基原:为豆科植物槐的果实。化学成份:含9个黄酮类和异黄酮类化合物,其中有染料木素、槐属甙、槐属双甙、山柰酚糖甙-C、槐属黄酮甙和芸香甙、芸香甙的含量很高,幼果中达46%。槐属甙含量为1.5-2.0%.槐属黄酮甙含量为0.8%。另含槐糖0.4%。种子含油9.9%。游离或结合的脂肪酸中,油酸为22.3%,亚油酸为53%,亚麻酸为12%。药理作用:1.抗生育作用:槐角中含的槐角甙、染料木素和山柰酚对小鼠具有抗生育作用和雌激素活性。2.其它作用:本品含大量芦丁。芦丁具抗炎作用和维生素P样作用。具有维持血管抵抗力,降低其通透性,减少脆性等作用,对脂肪浸润的肝有祛脂作用。还有抗病毒和抑制醛糖还原酶的作用。本品所含的双黄酮甙具有较芦丁更强的保护指质过氧化物酶和抗氧化物酶的作用。性味:苦,寒。归经:入肝、大肠经。功能主治:清热,润肝,凉血,止血。治肠风泻血,痔血,崩漏,血淋,血痢,心胸烦闷,风眩欲倒,阴疮湿痒。
黄珠子草:基原:为大戟科植物黄珠子草的全草或根。性味:①《南宁市药物志》:“甘苦。”②《广西中药志》:“甘,平。”功能主治:①《南宁市药物志》:“全草:消食,退翳。治疳积及疳积入眼。”②《广西药植名录》:“全草:补脾胃,治淋病,骨哽喉,小儿疳积。根:治乳房脓肿。”
土丁桂:基原:为双子叶植物药旋花科植物土丁桂的全草。化学成份:全草含黄酮甙、酚类酸、糖类、三十五烷,三十烷,β-谷甾醇,甜菜碱以及一种熔点为60-61℃的水溶性碱。药理作用:水溶性碱小剂量(0.02mg)能削弱在位蛙心的收缩力,减慢心率;大剂量(0.1mg)则使其停于舒张期。在1:500000-250000浓度时,能减少离体兔小肠的收缩幅度,增加其张力。性味:甘苦;凉。归经:肝;脾;肾经。功能主治:清热;利湿;解毒。主黄疸;痢疾;淋浊;带下;疗肿;疥疮。
棕树心:基原:为棕榈科植物棕榈的心材。性味:味苦;涩;性平。归经:心;脾经。功能主治:养心安神;收敛止血。主心悸;头昏;崩漏;脱肛;子宫脱垂。
人参:基原:为五加科植物人参的根。性味:甘微苦,温。归经:入脾、肺经。功能主治:大补元气,固脱生津,安神。治劳伤虚损,食少,倦怠,反胃吐食,大便滑泄,虚咳喘促,自汗暴脱,惊悸,健忘,眩晕头痛,阳痿,尿频,消渴,妇女崩漏,小儿慢惊,及久虚不复,一切气血津液不足之证。
草豆蔻:基原:为婪科植物草豆蔻的种子团。化学成份:种子含山姜素、小豆蔻明。性味:辛,温。归经:入脾、胃经。功能主治:温中燥湿;行气健脾。主寒湿阴滞脾胃之脘腹冷痛;痞满作胀,呕吐;泄泻;食谷不化;痰馀;脚气;阐疟;口臭。
琴叶榕:基原:为桑科植物琴叶榕的根、叶。性味:味甘、微辛、性平。功能主治:祛风除湿;解毒消肿;活血通经。主风湿痹痛;黄疽;疟疾;百日咳;乳汁不通;乳痈;痛经;闭经;痈疖肿痛;跌打损伤;毒蛇咬伤。
铜锤草:基原:为醉浆草科植物红花酢浆草的全草。化学成份:含草酸盐。药理作用:同属植物毛蓖醉浆草Oxaliscernua亦含草酸,牲畜(牛)食之,可得Oxalissyndrome病。主要为血中非蛋白氮水平异常增高,肾脏也有病变。性味:味酸;性寒。归经:肝;大肠经。功能主治:散瘀消肿;清热利湿;解毒。主跌打损伤;有经不调;咽喉肿痛;水泻;痢疾;水肿;白带;淋浊;痔疮;痈肿;疮疖;烧烫伤。
琥珀:基原:为古代松科植物的树脂埋藏地下经久凝结而成的碳氢化合物。化学成份:主含树脂、挥发油。此外,含有琥珀氧松香酸、琥珀松香酸、琥珀银松酸、琥珀脂醇、琥珀松香醇及琥珀酸等。性味:甘,平。归经:入心、肝、小肠经。功能主治:镇惊安神,散瘀止血,利水通淋。治惊风癫痫,惊悸失眠,血淋血尿,小便不通,妇女闭经,产后停瘀腹痛,痈疽疮毒,跌打创伤。
追风伞:基原:为报春花科星宿菜属植物狭叶落地梅的全草或根。药性:辛,温。功用主治:祛风通络,活血止痛。主治风湿痹痛,半身不遂,小儿惊风,跌打,骨折。
试验例1本发明所得医治心律失常的中药制剂(实施例5)的临床应用:
2010年7月-2013年5月,在5所医院筛选336例心律失常患者,其中男性共183例,女性153例,年龄在39-71岁,病程最短半年,最长7年,所有患者中的共同症状表现为:心悸、气短、胸闷、头晕、自觉乏力、脉结代或凝涩细弱,舌质淡紫或暗紫色,舌苔白腻,患者自觉有漏搏感;并经心电图检查确诊。将所有患者随机分为两组,实验组和对照组,实验组服用本发明所得产品,服用方法是:每天三次,每次8-10丸,温水送服,7天一个疗程。对照组服用其它药品(如稳心颗粒、心宝丸、心律平等常规药品)。共观察治疗四个疗程。疗效情况判定标准:痊愈:临床症状及体征全部消失,心电图恢复正常,半年后回访无复发者;显效:临床症状及体征显著改善,心电图恢复至正常或大致正常;有效:临床症状及体征明显减轻,心电图有效改善;无效:临床症状及体征无改善,心电图与治疗前无明显变化。(总有效率=痊愈率+显效率+有效率)结果如表1所示。
表1:实验组和对照组患者的治疗结果
治疗效果:实验组痊愈157例(72%),显效39例(17.9%),有效18例(8.3%),无效4例(1.8%),总有效率98.2%。实验组治疗效果明显优于对照组。
本发明选择白芍、太白参、石首鱼、缬草、万年青、槐角、黄珠子草、土丁桂、棕树心和人参等共15味主要原料药制备而成。方中,白芍具有平肝止痛,敛阴止汗的功效;太白参滋阴补肾,益气健脾;石首鱼益气健脾,补肾;缬草中某些成分对动物(犬、猫、兔、小鼠)有降低血压的作用;万年青甙增强心肌的收缩力,并能兴奋迷走神经和抑制心肌的传导,使心率减慢,并有利尿作用;槐角具有维持血管抵抗力,降低其通透性,减少脆性等作用;棕树心养心安神,收敛止血;草豆蔻温中燥湿,行气健脾;追风伞祛风通络,活血止痛。全方配伍,共奏滋养心阴,宁心安神,去瘀通脉的功效。治疗四个疗程,实验组总有效率为98.2%,而对照组仅为78%。
应当指出的是,具体实施方式只是本发明比较有代表性的例子,显然本发明的技术方案不限于上述实施例,还可以有很多变形。本领域的普通技术人员,以本发明所明确公开的或根据文件的书面描述毫无异议的得到的,均应认为是本专利所要保护的范围。
Claims (10)
1.医治心律失常的中药制剂,其特征在于,由下列原料药制备而成,均为重量份:白芍10-15;太白参8-16;石首鱼9-14;缬草4-9;万年青7-14;槐角6-12;黄珠子草8-13;土丁桂7-12;棕树心9-13;人参11-16;草豆蔻7-15;琴叶榕9-12;铜锤草10-13;琥珀8-12;追风伞9-15。
2.如权利要求1所述的医治心律失常的中药制剂,其特征在于,由下列原料药制备而成,均为重量份:白芍11-14;太白参10-14;石首鱼10-13;缬草5-8;万年青9-12;槐角8-10;黄珠子草9.5-11.5;土丁桂8.5-10.5;棕树心10-12;人参12.5-14.5;草豆蔻9-13;琴叶榕10-11;铜锤草11-12;琥珀9-11;追风伞11-13。
3.如权利要求1所述的医治心律失常的中药制剂,其特征在于,由下列原料药制备而成,均为重量份:白芍12.5;太白参12;石首鱼11.5;缬草6.5;万年青10.5;槐角9;黄珠子草10.5;土丁桂9.5;棕树心11;人参13.5;草豆蔻11;琴叶榕10.5;铜锤草11.5;琥珀10;追风伞12。
4.如权利要求1-3所述的医治心律失常的中药制剂,其特征在于,将其制成药学上可接受的丸剂,制备方法如下:
(1)取石首鱼肉置于容器中,加入15%原料药量的黄酒拌匀,焖6-14分钟(优选焖10分钟),然后捣碎成泥状,备用;琥珀研成细粉,置乳钵中,水飞至无声为度,干燥,备用;
(2)取太白参、人参和棕树心置于砂锅内,加3-5倍量的清水(优选加4倍量的清水),文火加热煎煮25-45分钟(优选文火加热煎煮35分钟),过滤,滤液备用;
(3)取缬草、万年青、黄珠子草、草豆蔻、琴叶榕和铜锤草于68-76℃干燥26-42分钟(优选于72℃干燥34分钟),然后置于粉碎机中粉碎成细粉,备用;
(4)将白芍、槐角、土丁桂和追风伞置于药锅内,加冷水没过药面3-4cm,大火加热至沸,转小火煎煮22-46分钟(优选转小火煎煮34分钟),过滤,滤液与步骤(2)所得滤液合并,减压浓缩至原体积的的1/4,备用;
(5)将步骤(1)和(3)处理后的原料要加入到步骤(4)所得滤液中,加入其它辅料,搅拌均匀,干热灭菌,加工成赤豆大小的丸剂,即得。
5.根据权利要求4所述的医治心律失常的中药丸剂的制备方法,其特征在于,步骤(5)中所述辅料为质量分数为10%的乳糖细粉和质量分数为6%的玉米淀粉。
6.根据权利要求4所述的医治心律失常的中药丸剂的制备方法,其特征在于,步骤(5)中干热灭菌的温度为85-105℃(优选的干热灭菌的温度为90-100℃,更加优选的干热灭菌的温度为95℃)。
7.根据权利要求4所述的医治心律失常的中药丸剂的制备方法,其特征在于,步骤(5)中干热灭菌的时间为32-54分钟(优选的干热灭菌的时间为38-48分钟,更加优选的干热灭菌的时间为43分钟)。
8.如权利要求1-3所述的医治心律失常的中药制剂,其特征在于,将其制成药学上可接受的胶囊剂,制备方法如下:
(1)取石首鱼肉、太白参、人参和土丁桂置于药锅内,加冷水没过药面3-5cm,然后中火煎煮18-36分钟(优选中火煎煮27分钟),过滤,滤液减压浓缩至原体积的1/3,备用;
(2)取草豆蔻加姜汁拌匀(草豆蔻:生姜=20:1),待姜汁被吸尽后,置炒制容器内,文火加热炒干,取出晾凉,捣碎成细粉,备用;琥珀研成细粉,置乳钵中,水飞至无声为度,干燥,备用;
(3)将除步骤(1)和(2)以外的原料药置于中药提取器中,以乙醇和水为溶剂(乙醇和水的体积比为1:2.5),溶剂的量为原料药量的4-7倍(优选溶剂的量为原料药量的5.5倍),加热回流提取两次,第一次提取22-48分钟(优选第一次提取35分钟),第二次提取10-24分钟(优选第二次提取17分钟),合并两次提取液,过滤,回收乙醇,减压蒸馏至80℃相对密度为1.30-1.33的稠膏,备用;
(4)将步骤(1)和(2)处理后的原料药加入到上述稠膏中,机械搅拌,同时加入其它辅料(辅料为质量分数为9.5%的糊精细粉和质量分数为5.5%的微晶纤维素),混合均匀,制粒,整粒,干燥,过六号筛,装入胶囊壳,即得。
9.如权利要求1-3所述的医治心律失常的中药制剂,其特征在于,将其制成药学上可接受的片剂,制备方法如下:
(1)取石首鱼肉加入15%原料药量的黄酒拌匀,置于蒸锅内,大火加热蒸熟为度,取出,捣碎成泥状,备用;
(2)草豆蔻、槐角、棕树心、琥珀、人参和太白参置于烘箱内,于45-65℃干燥1-3小时(优选于55℃干燥2小时),捣碎,并研细粉,备用;
(3)将除步骤(1)和(2)以外的原料药加3.5-6.5倍量的清水文火煎煮两次(优选加5倍量的清水文火煎煮两次),第一次煎煮32-50分钟(优选第一次煎煮40分钟),第二次煎煮11-33分钟(优选第二次煎煮22分钟),合并两次减压,过滤,滤液减压浓缩至75℃相对密度为1.25-1.28的稠膏,冷却至室温,加浓度为80%的乙醇,使含醇量为45%,静置20-30小时(优选静置25小时),过滤,滤液回收乙醇,减压浓缩至80℃相对密度为1.31-1.33的稠膏,备用;
(4)将步骤(1)处理后的石首鱼肉以及步骤(2)所得原料药粉加入到上述稠膏中,喷雾干燥得干膏粉,边搅拌边加入乳糖细粉和硬脂酸镁,干膏粉与乳糖细粉和硬脂酸镁的质量比为6:1.1:0.8,混合均匀,置于压片机中压成片剂,即得。
10.如权利要求1-3所述的医治心律失常的中药制剂,其特征在于,将其制成药学上可接受的水剂,制备方法如下:
(1)取槐角洗净,武火炒至表面焦黑色,内部深黄色,取出放凉,研细粉,备用;草豆蔻文火加热,炒至微黄色并有香气逸出为度,取出晾凉,捣碎成细粉,备用;琥珀置于研钵中研细粉,备用;
(2)取石首鱼肉、太白参和人参加清水没过药面3-4cm,文火加热煎煮26-46分钟(优选文火加热煎煮36分钟),过滤,滤液备用;
(3)棕树心、土丁桂、琴叶榕和追风伞混合,加入25%-35%原料药量的黄酒拌匀(优选加入30%原料药量的黄酒拌匀),焖1-3小时(优选焖2小时),取出,备用;
(4)将步骤(3)处理后的原料药与白芍、缬草、万年青、黄珠子草和铜锤草一同置于砂锅内,加5-7倍原料药量的清水(优选加6倍原料药量的清水),文火煎煮35-55分钟(优选文火煎煮45分钟),过滤,滤液备用;
(5)将步骤(2)和(4)所得滤液合并,减压浓缩至原体积的1/3,然后加入步骤(1)处理后的原料药粉,搅拌均匀,灭菌封装,即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510537963.XA CN105056073A (zh) | 2015-08-28 | 2015-08-28 | 医治心律失常的中药制剂及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510537963.XA CN105056073A (zh) | 2015-08-28 | 2015-08-28 | 医治心律失常的中药制剂及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105056073A true CN105056073A (zh) | 2015-11-18 |
Family
ID=54485743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510537963.XA Pending CN105056073A (zh) | 2015-08-28 | 2015-08-28 | 医治心律失常的中药制剂及制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105056073A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535852A (zh) * | 2016-01-21 | 2016-05-04 | 李宪秋 | 一种治疗心律失常的中药制剂 |
-
2015
- 2015-08-28 CN CN201510537963.XA patent/CN105056073A/zh active Pending
Non-Patent Citations (2)
| Title |
|---|
| 张庆祥: "《每天学点中医食疗》", 30 January 2014, 中国医药科技出版社 * |
| 祝丹等: "心律失常的中医用药及组方规律探讨", 《陕西中医学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535852A (zh) * | 2016-01-21 | 2016-05-04 | 李宪秋 | 一种治疗心律失常的中药制剂 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105194565A (zh) | 一种用于治疗心脏神经症的中药丸剂及制备方法 | |
| CN105687824A (zh) | 一种用于治疗产后盗汗的中药冲剂及制备方法 | |
| CN103933509B (zh) | 用于治疗淡水鱼水霉病的药物及其制备方法 | |
| CN103749824B (zh) | 一种绞股蓝降糖降压保健茶及其制备方法 | |
| CN104825914A (zh) | 一种辅助治疗乳腺癌症的中药制剂 | |
| CN104127813A (zh) | 一种治疗气血两虚型褥疮的中药组合物及其制备方法 | |
| CN102846824B (zh) | 一种治疗寒湿血瘀阻络型糖尿病足的中药组合物及其制备方法 | |
| CN104815037A (zh) | 一种治疗风湿蕴毒型慢性湿疹的药物及其制备方法 | |
| CN104147538A (zh) | 一种治疗湿热毒盛型糖尿病足的中药制剂及其制备方法 | |
| CN103933405A (zh) | 用于治疗气血两虚型烧伤的药物组合物及其制备方法 | |
| CN103989957A (zh) | 用于治疗胃阴亏虚型慢性胃炎的药物组合物及其制备方法 | |
| CN103933538A (zh) | 用于治疗脾肾阳虚型肝硬化腹水的药物及其制备方法 | |
| CN104043058A (zh) | 一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法 | |
| CN104324330A (zh) | 一种治疗淤血蓄结型子宫肌瘤的中药组合物及其制备方法 | |
| CN103656048A (zh) | 用于治疗奶牛乳房炎的药物及其制备方法 | |
| CN103301341A (zh) | 一种治疗缺血性脑中风的中药组合物 | |
| CN105056073A (zh) | 医治心律失常的中药制剂及制备方法 | |
| CN104147438A (zh) | 一种治疗气滞心胸胸痹的内服汤剂 | |
| CN105079392A (zh) | 治疗坐骨神经痛的制剂及其制备方法 | |
| CN105770760A (zh) | 主治胃溃疡的制剂及其制备方法 | |
| CN104707003B (zh) | 治疗高血压、高血脂的中药胶囊 | |
| CN105853843A (zh) | 一种临床用小儿伤口护理的药物组合物及其制备方法 | |
| CN103933359A (zh) | 用于祛除瘢痕疙瘩的药物组合物及其制备方法 | |
| CN105213749A (zh) | 用于治疗骨质疏松的制剂及制法 | |
| CN105287933A (zh) | 一种医治动脉硬化的健脾益气中药制剂及制法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 810000 Qinghai Province, Eastern District of Xining City Garden No. 21 North Street, building 3, Oriental Pearl 2-501 Applicant after: Huo Tongyan Address before: 250000 Shandong, Ji''nan, East Industrial and Commercial Road Flyover District No. 13 Applicant before: Huo Tongyan |
|
| COR | Change of bibliographic data | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151118 |